Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Buspirone hydrochloride Clear all
Completed Phase 2 Interventional

Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1

NCT00149617
View directory record Official record
Conditions
Marijuana Abuse, Mood Disorders
Interventions
Buspirone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 7, 2026, 11:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Spinal Cord Neuromodulation for Spinal Cord Injury

NCT02313194
View directory record Official record
Conditions
Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia
Interventions
Epidural Stimulation, Buspirone
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems

NCT01743235
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, Testosterone, Buspirone hydrochloride
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
San Diego, California • Bradenton, Florida • North Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Intravascular Cooling in the Treatment of Stroke 2/3 Trial

NCT01123161
View directory record Official record
Conditions
Stroke, Acute
Interventions
hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years to 82 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

NCT02458469
View directory record Official record
Conditions
Spinal Cord Injury, Sleep Disordered Breathing
Interventions
Buspirone, Trazodone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01843205
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
Methamphetamine, Placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

NCT00270959
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional

Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy

NCT00166621
View directory record Official record
Conditions
Autism
Interventions
Buspirone
Drug
Lead sponsor
Chugani, Diane C.
Individual
Eligibility
2 Years to 6 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

NCT00705003
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone), Matching placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Improving Ventilatory Capacity in Those With Chronic High Level SCI

NCT05041322
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buspirone Hydrochloride 30mg Tablets, Non-Fasting

NCT00840398
View directory record Official record
Conditions
Healthy
Interventions
BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

NCT01639157
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Buspirone, Placebo
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional Results available

Piloting Acute Care to Primary Care Linkage of Safety Net Patients

NCT01347541
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Psychopharmacology for Cocaine Dependence - Buspirone

NCT01267292
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo for Buspirone, Methylphenidate, Placebo for Methylphenidate
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Buspirone for Early Satiety and Symptoms of Gastroparesis

NCT03587142
View directory record Official record
Conditions
Gastroparesis
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Buspirone for Opioid Tapering

NCT03521960
View directory record Official record
Conditions
Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
Interventions
Buspirone oral capsule, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 7, 2026, 11:02 AM EDT
Active, not recruiting Early Phase 1 Interventional

Transformation of Paralysis to Stepping

NCT04105114
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone, Non-invasive Spinal Cord Stimulation, Overground stepping, Gravity Neutral Device, Body Weight Supported Treadmill Training, Rolling Walker
Drug · Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

Buspirone Treatment for Marijuana Dependence

NCT00875836
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 7, 2026, 11:02 AM EDT
Active, not recruiting Phase 2 Interventional

Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury

NCT04458324
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Buspirone Hydrochloride, Buspirone placebo, Noninvasive Ventilation (NIV), Sham Non-invasive ventilation (NIV), Functional Electrical Stimulation Row Training (FESRT)
Drug · Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

NCT01395953
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
Buspirone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 7, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Evaluating Buspirone to Treat Opioid Withdrawal

NCT05511909
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety
Interventions
Buspirone, Lofexidine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 7, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Buspirone, Stress, and Attentional Bias to Marijuana Cues

NCT02132832
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Buspirone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 7, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 7, 2026, 11:02 AM EDT